Logo

OACCU

Oaktree Acquisition Corp. III Life Sciences Unit

OACCU

Oaktree Acquisition Corp. III Life Sciences Unit • NASDAQ
$10.95 ▲ 0.00% (+0.00)
Market Cap $269.46 M
52w High $11.06
52w Low $10.03
Dividend Yield 0%
P/E 0
Volume 504
Outstanding Shares 24.61M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $225.579K ▼ $1.967M ▲ 0% $0.08 ▲ $0 ▲
Q2-2025 $0 $269.81K ▼ $1.874M ▲ 0% $0.076 ▲ $-269.81K ▼
Q1-2025 $0 $444.802K ▲ $1.659M ▲ 0% $0.068 ▲ $1.659M ▲
Q4-2024 $0 $303.711K ▲ $1.38M ▲ 0% $0.056 ▲ $-303.711K ▼
Q3-2024 $0 $48.095K $-48.095K 0% $-0.002 $-48.095K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.329M ▼ $201.25M ▲ $8.246M ▲ $-6.765M ▼
Q2-2025 $1.385M ▲ $199.176M ▲ $8.138M ▲ $191.038M ▲
Q1-2025 $1.281M ▼ $197.241M ▲ $8.077M ▲ $189.163M ▲
Q4-2024 $1.357M ▲ $195.251M ▲ $7.746M ▲ $187.505M ▲
Q3-2024 $0 $638.992K $662.087K $-23.095K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $1.967M ▼ $-56.518K ▲ $191.99M ▲ $-193.437M ▼ $-56.518K ▼ $-56.515K ▲
Q2-2025 $2.153M ▲ $-131.998K ▼ $250K ▲ $0 ▼ $28.315K ▼ $-131.998K ▼
Q4-2024 $1.38M ▲ $-89.687K ▼ $-191.99M ▼ $193.437M ▲ $1.357M ▲ $-89.687K ▼
Q3-2024 $-48.095K $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement OACCU is essentially a blank‑check shell at this stage, so its income statement is very simple: no meaningful revenue and no underlying operating business yet. Any small reported profit mostly reflects interest on cash rather than true business performance. Until a merger target is announced and completed, there is no real way to judge margins, growth, or earnings quality – they will all depend entirely on the future company it combines with.

Balance Sheet

Balance Sheet The balance sheet is light and clean, which is typical for a newly listed SPAC. It mainly consists of cash and equivalents, with no notable operating assets, no visible debt load, and equity representing the capital raised from investors. The real economic substance sits in the trust cash and the sponsor’s commitment; actual asset strength, leverage, and capital intensity will only become clear once a business combination is identified and completed. For now, financial risk looks low, but visibility into the eventual post‑merger balance sheet is also low.

Cash Flow

Cash Flow Cash flows are minimal and mostly mechanical. There is no true operating cash inflow or outflow because there is no active business; cash movements mainly reflect IPO proceeds, trust management, and routine listing and administrative costs. There is no investment spending or capital expenditure to analyze yet. Future cash generation, reinvestment needs, and free cash flow will depend entirely on the quality and capital intensity of the target company OACCU ultimately acquires.

Competitive Edge

Competitive Edge As a SPAC, OACCU’s competitive position is not about products or services, but about its ability to source and negotiate an attractive deal. Its main asset is the Oaktree brand and network, which can help in accessing higher‑quality life sciences or healthcare targets compared with less established sponsors. At the same time, it faces stiff competition from other SPACs, private equity, and strategic buyers chasing similar companies, plus higher regulatory and market scrutiny of SPAC deals in general. The eventual competitive position will be determined far more by the chosen merger partner than by OACCU itself.

Innovation and R&D

Innovation and R&D OACCU itself does not run an operating business, so it has no in‑house research and development. The background material you provided focuses on Hims & Hers, a tech‑driven healthcare platform that emerged from a prior Oaktree SPAC and illustrates the kind of data‑heavy, AI‑enabled model Oaktree has backed before. That history suggests the sponsor is comfortable with companies that lean on proprietary technology, personalization, and subscription models, particularly in healthcare. However, for this vehicle, any innovation profile or R&D intensity will be entirely determined by the eventual target company and is highly uncertain at this point.

Summary

OACCU is an early‑stage SPAC with no operating business, no revenue, and a very simple, cash‑heavy balance sheet, which makes current financials easy to read but not very informative about long‑term prospects. Its risk/return profile hinges almost entirely on whether management can identify, negotiate, and close a compelling merger in the life sciences or healthcare space, and on how many shareholders redeem at that time. The Oaktree sponsorship and prior experience backing innovative, tech‑enabled healthcare companies are clear strengths, but they do not guarantee that the next deal will be equally successful. Until a concrete target and transaction terms are announced, visibility into future earnings power, growth, competitive advantages, and innovation is limited, and the vehicle is best viewed as a pool of cash with embedded deal execution and market risks rather than a traditional operating company.